Epithelial ovarian cancer in elderly
Conditions
Interventions
Case group:None
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. The age of EOC patients who are first diagnosed and treated in each center is = 70 years old; 2. All patients received standard staging, primary tumor cell reduction or intermediate tumor cell reduction, and EOC confirmed by two or more chief physicians of pathology department before enrollment; 3. The diagnosis time of the enrolled patients must be between January 1, 2018 and December 31, 2023. The last enrolled patient should be followed up for at least 12 months; 4. The relevant clinical data of the patient is complete: age, BMI, complications and family history at the time of cancer diagnosis; Tumor markers (CA125/CA199/HE4), blood routine, albumin and prealbumin, CRP, D-dimer, imaging data before treatment; The amount of ascites seen during the operation, the score of SCS and DDS, the operation type, the operation time, the size and location of the primary pathological focus after the operation, the size and location of lymph nodes and whether they are metastatic, the postoperative complications, chemotherapy (drug, dose, course of treatment, sensitivity), recurrence and survival; 5. The patient may have a history of breast cancer, and has been cured for nearly 2 years when he was enrolled without treatment or relapse; 6. For patients with neoadjuvant chemotherapy, if CA125/CEA<25, gastrointestinal endoscopy is required to exclude the source of digestive tract; 7. When participating in the study, patients who voluntarily signed the informed consent form approved by the Research Ethics Committee (EC) will understand the potential risks, benefits and discomfort of participating in the study after properly informing the nature of the study.
Exclusion criteria
Exclusion criteria: 1.There is no clear pathological diagnosis basis; 2.Patients who have participated in other biomedical studies or received experimental therapy within the past 30 days, unless approved by the investigator; 3.There are known contraindications to the upcoming first-line chemotherapy or second-line or multi-line chemotherapy; 4.Have a history of malignant tumors or co-existing other malignant tumors or multiple primary tumors (excluding breast cancer); 5.With HIV, hepatitis B, hepatitis C and other active infectious diseases or active rheumatic system diseases; 6.Ineligible for inclusion, such as severe or uncontrolled bacterial, fungal, or viral infection or other conditions that may interfere with patients' participation in the study or evaluation of the study results; 7.The main information is not complete or the patients are lost to follow-up without reason during the study; 8.Unwillingness to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactZhou Ying
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed